Earnings Feed
Start Free
Home/Filings/4/0001855763-24-000005
4//SEC Filing

BUNKA CHRISTOPHER 4

Accession 0001855763-24-000005

CIK 0001348362other
View on SEC.govCompany Profile

Filed

May 9, 8:00 PM ET

Accepted

May 10, 4:44 PM ET

Size

14.4 KB

Accession

0001855763-24-000005

Insider Transaction Report

Form 4
Period: 2024-04-26
Lexaria Bioscience Corp.LEXX
BUNKA CHRISTOPHER
DirectorChariman/CEO/President/CFO
Transactions
  • Award

    Stock Options

    2024-04-26+49,500→ 180,501 total
    Exercise: $2.36From: 2024-04-26Exp: 2029-04-26→ Common Shares (49,500 underlying)
Holdings

  • common shares

    273,543

  • Stock Options

    Exercise: $2.91From: 2022-08-29Exp: 2027-08-29→ Common Shares (30,000 underlying)
    101,001

  • common shares

    (indirect: Private Holding Company)
    254,412

  • Warrants

    (indirect: Private Holding Company)
    Exercise: $10.50From: 2020-05-06Exp: 2025-05-06→ Common Shares (6,667 underlying)
    6,667

  • Stock Options

    Exercise: $3.00From: 2021-06-08Exp: 2026-06-08→ Common Shares (23,334 underlying)
    56,001

  • Stock Options

    Exercise: $1.15From: 2023-10-26Exp: 2028-10-26→ Common Shares (30,000 underlying)
    131,001

  • Stock Options

    Exercise: $3.00From: 2021-04-26Exp: 2026-04-26→ Common Shares (26,000 underlying)
    32,667

  • Stock Options

    Exercise: $3.00From: 2021-09-01Exp: 2026-09-01→ Common Shares (15,000 underlying)
    71,001
Footnotes (3)
  • [F1]Repriced from $5.83 pursuant to shareholder approval received on May 9, 2023
  • [F2]Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023
  • [F3]Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023

Documents

1 file

Issuer

Lexaria Bioscience Corp.

CIK 0001348362

→
Entity typeother

Related Parties

1
  • filerCIK 0001103780

Filing Metadata

Form type
4
Filed
May 9, 8:00 PM ET
Accepted
May 10, 4:44 PM ET
Size
14.4 KB
View on SEC.gov